KROS — Keros Therapeutics Share Price
0.000.00%
Last trade - 00:00- $2.11bn
- $1.78bn
- $0.15m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.35 | ||
| Price to Tang. Book | 6.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13,966.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.17% | ||
| Return on Equity | -50.19% | ||
| Operating Margin | -112543.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10 | n/a | 20.1 | n/a | 0.15 | 6.3 | 0.02 | -56.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Directors
- Jasbir Seehra CEO (65)
- Keith Regnante CFO (51)
- Christopher Rovaldi COO (47)
- Jennifer Lachey CSO (48)
- Simon Cooper OTH (52)
- Nima Farzan IND (45)
- Carl Gordon IND (56)
- Mary Gray IND (68)
- Tomer Kariv IND (60)
- Julius Knowles IND (58)
- Ran Nussbaum IND (48)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 9th, 2015
- Public Since
- April 8th, 2020
- No. of Shareholders
- 15
- No. of Employees
- 136
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 35,982,628
- Address
- 1050 Waltham Street, Suite 302, LEXINGTON, 02421
- Web
- https://www.kerostx.com/
- Phone
- +1 6173146297
- Contact
- Justin Frantz
- Auditors
- Deloitte & Touche LLP
Upcoming Events for KROS
Keros Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Keros Therapeutics Inc Earnings Release
Similar to KROS
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Keros Therapeutics share price?
As of Today at 19:12 UTC, shares in Keros Therapeutics are trading at $58.61. This share price information is delayed by 15 minutes.
How has the Keros Therapeutics share price performed this year?
Shares in Keros Therapeutics last closed at $58.61 and the price had moved by +47.78% over the past 365 days. In terms of relative price strength the Keros Therapeutics share price has outperformed the S&P500 Index by +19.35% over the past year.
What are the analyst and broker recommendations for Keros Therapeutics?
The overall consensus recommendation for Keros Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Keros Therapeutics dividend yield?
Keros Therapeutics does not currently pay a dividend.
Does Keros Therapeutics pay a dividend?
Keros Therapeutics does not currently pay a dividend.
When does Keros Therapeutics next pay dividends?
Keros Therapeutics does not currently pay a dividend.
How do I buy Keros Therapeutics shares?
To buy shares in Keros Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Keros Therapeutics?
As of the previous close price of $58.61, shares in Keros Therapeutics had a market capitalisation of $2.11bn.
Where are Keros Therapeutics shares listed?
Here are the trading details for Keros Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: KROS
What kind of share is Keros Therapeutics?
Based on an overall assessment of its quality, value and momentum Keros Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Keros Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Keros Therapeutics is $88.88. That is 51.65% above the last closing price of $58.61.
Analysts covering Keros Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$5.27 for the next financial year.
What is the trend in the Keros Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Keros Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +77.99%.
As of the last closing price of $58.61, shares in Keros Therapeutics were trading +34.85% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Keros Therapeutics PE Ratio?
The Keros Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $58.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Keros Therapeutics?
Keros Therapeutics' management team is headed by:
- Jasbir Seehra - CEO
- Keith Regnante - CFO
- Christopher Rovaldi - COO
- Jennifer Lachey - CSO
- Simon Cooper - OTH
- Nima Farzan - IND
- Carl Gordon - IND
- Mary Gray - IND
- Tomer Kariv - IND
- Julius Knowles - IND
- Ran Nussbaum - IND